Articles tagged with Drug Development
A team of scientists from the Beckman Institute has received a $3 million grant to develop diagnostic tools and imaging agents for the early detection of Alzheimer's disease. They will use a combination of PET and MRI scans to target smaller beta-amyloid peptides and other signs of neuroinflammation and oxidative stress.
A study reveals thyroid cancer's genetic changes contribute to resistance to BRAF inhibitors and can lead to tumor dedifferentiation. Researchers identify potential targets for new therapies, including dual-targeted treatments and immunotherapy combinations.
Researchers at Tokyo University of Science have developed a novel approach to synthesize dibenzothiophene s-oxides, which feature highly reactive functional groups. This method surpasses conventional methods and enables the creation of a wide range of molecules with diverse properties.
Researchers develop technology that alleviates retinal pathologies by targeting mitochondrial chaperone TRAP1, which is implicated in the breakdown of blood-retinal barrier and pathological neovascularization. This treatment approach holds great promise for revolutionizing the treatment landscape for ischemic retinopathy.
Researchers developed a new reagent called t-BuSF to improve the synthesis of sulfur-containing compounds used in medicines. The use of t-BuSF decreased reaction times and improved stability, enabling efficient production of these compounds.
A phase 3 trial has shown that the novel drug acoramidis achieves near-complete stabilization of TTR proteins, slowing or halting disease progression. The treatment reduced hospitalizations for heart-related events and increased distance walked over six minutes.
Scientists have identified likely 'cells-of-origin' that can grow into breast cancer in women carrying a faulty BRCA2 gene, who are at high risk of developing the disease. The study also showed these cells have potential to be targeted with an existing cancer drug to delay tumour growth.
The study classifies pediatric acute myeloid leukemia (pAML) into 23 distinct molecular categories, revealing unique biological characteristics and drivers of the disease. This classification provides a path forward for clinicians to identify distinct pAML sub-types and guide treatment decisions.
Researchers found a shared genetic trait that predicts a higher risk of small lung vessel disease and its severe form, pulmonary arterial hypertension. This discovery could lead to personalized treatments for patients with limited oxygen response.
The University of Rochester is establishing a new NIH-funded center focused on developing FDA-qualified drug development tools related to barrier functions in disease. Researchers will create microphysiological systems with ultrathin membranes of human cells, aiming to reduce animal trials and improve drug efficacy.
A new trial found that combining anti-angiogenic drugs with chemotherapy led to more young people seeing their tumors shrink, from 18% in the control group to 26%. Patients who received Bevacizumab additionally had better one year progression-free survival rates.
A team at UNC-Chapel Hill has developed a new process for synthesizing amides with 100% atom efficiency, employing environmentally friendly cobalt. This approach offers an attractive alternative to traditional methods, which often generate waste and poor atom economy.
Scientists at the University of Bath have found that the gene Angiogenin plays an important role in the development of nerve cells. In its mutated form, it causes stem cells to persist in their original state longer than they should, resulting in neurodevelopmental defects.
A new consortium, co-led by Florian Rieder, MD, and Vipul Jairath, MD, will create clinical care pathways toward drug development and improve disease management for patients with Crohn's disease and permanent ileostomy. The EndO-trial Consortium aims to develop effective drugs and measure treatment outcomes using patient-reported outco...
Researchers have developed a new method to generate cyclic peptides that can target diseases and be administered orally, overcoming challenges in protein binding. The approach enables high-throughput screening and has shown substantial bioavailability in rats, opening possibilities for treating various diseases.
The number of new dermatologic drug approvals by the FDA increased significantly between 2012 and 2022, with nearly half considered first in class or indication. This surge in approvals was deemed clinically useful or to have high added therapeutic benefit by health technology assessment organizations.
A team of researchers has identified the allosteric control sites found in the protein KRAS, providing a comprehensive map for controlling its effects. The study offers promising targets for safer and more effective drugs, with potential implications for cancer treatment.
A novel inhibitor drug, KRB-456, has been discovered to target the KRAS G12D mutation in pancreatic cancer patient-derived tumors. The study demonstrates that KRB-456 significantly inhibits tumor growth in mice, offering a promising therapeutic option for KRAS-driven cancers.
A study by Waseda University explores the effects of different vascularization strategies on brain organoids, improving cell differentiation and transcriptome profiles. Vascularized cerebral organoids exhibit a gene expression profile closer to fetal human brains than non-vascularized ones.
Researchers explore quantum optical technology to solve scalability and accuracy issues in quantum computing, aiming to develop new drugs faster and more efficiently. Photon-based systems offer a solution by reducing physical components, increasing opportunities for scaling and stability.
Klick Applied Sciences unveils LOVENet, an AI framework that rapidly identifies new therapeutic indications for existing drugs. The algorithm integrates large language model and structured knowledge graph technology to offer a fresh perspective on new potential applications.
Researchers have identified promising treatment candidates for morphine tolerance and cancer, as well as a biomarker for kidney injury. A monoclonal antibody targeting the mu-opioid receptor has been shown to alleviate morphine tolerance and physical dependence, while inducing excessive mitochondrial fission in tumor cells. Additionall...
Researchers at IISc create a novel technique to coat droplets in composite shells containing oil-loving and hydrophobic particles. This method offers flexible shell thickness control over a wide range, enabling the encapsulation of droplets with different sizes.
Researchers at University of Cincinnati Cancer Center present Phase 2 clinical trial results for a new BTK inhibitor treatment that offers potential for improved efficacy and safety in chronic lymphocytic leukemia. The study also explores the use of IRAK4 inhibitors to target acute myeloid leukemia cells, with promising results.
Scientists at IPC PAS create peptide-based sensors to detect inflammation and chronic diseases, offering a promising alternative to traditional methods. The study uses phage-display method to identify CRP-binding peptides, achieving higher affinity and detection efficiency than antibodies.
Researchers have provided new details on structures resulting from 3D domain swapping in antibody light chains, shedding light on mechanisms of protein aggregation. The study suggests that the formation of tetramers may prevent protein aggregation by decreasing flexibility.
Researchers at the University of Turku found that bexmarilimab therapy alters macrophage behavior to promote anti-tumor immune defense. The therapy was well-tolerated and stabilized disease progression in patients with advanced-stage cancer, inducing tumor-associated macrophage and lymphocyte activation.
Researchers have discovered that a nanoemulsion made from copaiba oil has antiviral effects against zika virus, showing 80% viral RNA inhibition. The study's results pave the way for developing medications or specific vaccines against zika.
A new experimental model, human precision-cut lung slices (hPCLS), was used to study lung disease mechanisms and understand treatment response. The team leveraged single-cell genomics to analyze cell activity in hPCLS after specific treatments.
Researchers discovered how biological information travels between mothers and babies during pregnancy. Microscopic extracellular vesicles, produced by placental cells, act as a protective mechanism transporting important biological information to emerging neurons.
Researchers analyzed leishmaniasis lesions on mouse skin to detect metabolic signaling pathways that differed from uninfected mice. They found pathways with pain-relief properties tied to the brain's endocannabinoid system, which is involved in a host of physiological processes, including the pain response.
CureSHANK is offering $250,000 grants to researchers studying SHANK3-related epilepsy in Phelan-McDermid syndrome. The goal is to improve mechanistic and clinical knowledge of this treatment-resistant form of epilepsy.
Researchers have developed new tools to assess disease progression of Alzheimer's disease in animal models, providing a translational approach for studying the disease. The tools use neuroimaging and network modeling techniques to analyze metabolic changes in the brain, confirming previous clinical findings.
A team of researchers successfully synthesized a 1.5-million-year-old antibiotic called paleomycin, which displays potent properties against human pathogens. By tracing the evolutionary path of glycopeptide antibiotics, the team gained insights into the development of new drugs and uncovered a common precursor molecule.
Researchers at Kyoto University developed a new reactant demonstrating efficacy on proteins with drug-resistant mutations. The new inhibitor, ArNASA, reacts with lysine residues and is highly stable in physiological environments.
Disrupted health care markets have changed the creation, provision, and consumption of health care. Marketing strategies need to account for new producers, providers, and consumers. The editorial calls for a research agenda outlining opportunities for marketing scholars to examine the impact of disrupted exchanges on consumer welfare.
The study reveals that mutations of the p53 protein are critical for driving cancer growth, and its loss-of-function is the primary contributor. Researchers used CRISPR to remove mutated versions of the protein and found no evidence of gain-of-function contributing to cancer growth.
Researchers at the University of Bath have created a novel bacterial system to mass-produce cyclic proteins and peptides, addressing a significant bottleneck in the development of new therapeutic treatments. By harnessing the natural cyclization process from the Oldenlandia flower, they improved heat and chemical stability, as well as ...
Researchers at iGCORE in Japan developed two synthetic versions of an ADP-ribose fragment to study cellular functions. The approach enables the production of structurally well-defined oligo- and poly(ADP-ribose) samples, accelerating ADP-ribose biology research.
Researchers at Cornell University have found that silica-based C’Dots can be taken up by the bloodstream after oral administration, making them a potential therapeutic delivery method. The particles' ability to induce ferroptosis, a cell death program, may also provide health benefits due to their natural presence in food.
Researchers have developed a new method, SECRE, to identify genetic regulators of cytokine secretion in autoimmune diseases. The technique has been validated on cells known to play a crucial role in inflammatory bowel disease (IBD) and shows promising results for treating conditions with few therapeutic options.
Researchers have successfully mapped the entire HLA class II landscape, predicting how pathogens are displayed on cell surfaces. The mapping reveals that multiple HLA variants play essential roles in autoimmune disorders and organ rejection, highlighting their potential for developing immunotherapy treatments.
Scientists at ETH Zurich used AI to analyze data from 1,380 borylation reactions and predict optimal synthesis methods for new drugs. The model was tested on six known drug molecules and showed a success rate of five out of six cases.
A team of researchers has found a way to get antibacterial drugs through the outer membrane of Pseudomonas aeruginosa, making it more vulnerable to treatment. By using machine learning and testing various compounds, they discovered how to create new compounds that can penetrate the bacterium's defenses.
Researchers at University of Eastern Finland developed a new method for accurate determination of water content in water-soluble compounds, utilizing solution-state nuclear magnetic resonance spectroscopy. The method is simple, accurate and quick, with results comparable to traditional methods like TGA and X-ray crystallography.
Researchers at Chalmers University of Technology have discovered a new method for capturing proteins in nano-sized traps to study difficult-to-treat diseases. The technique allows for the trapping of hundreds of proteins in a small volume, enabling the study of early development and potential drug countermeasures.
Researchers developed an ingestible capsule to measure vital signs from within the GI tract, detecting sleep apnea episodes and breathing rate depression. The device shows promise for early detection of respiratory changes, including those caused by opioids or asthma/COPD.
A small molecule called YM022 has been discovered to block aversive memory formation in mice, offering a new direction for developing anti-depressants. The study found that YM022 suppressed neuroplasticity-caused aversive memory formation and reduced depressive behaviors in mice.
Researchers have created a reliable and efficient method to add fluorine to molecules, increasing pharmaceutical drug efficiency. The iron and sulfur-based reaction enables the release of fluorine from carboxylic acids and its incorporation into alkenes, common building blocks for drugs.
Jenny Wilkerson receives $1.94 million grant to develop novel models and investigate antinociceptive profiles of basal sex hormone alterations in patients with chronic post-op pain. The study aims to answer questions about the impact of altered sex hormone levels on recovery times, drug effectiveness, and long-term health.
Experts have developed a reliable method to predict the free energy of crystals, addressing the challenge of understanding physical properties and environmental factors. The new approach uses high-performance computing and has been successfully applied to seven pharmaceutical companies.
A novel device, ecO2, produces oxygen at the site to keep cells alive for up to a month in vitro or weeks in vivo. This innovation improves the outcomes of cell-based therapies for diseases and injuries by increasing metabolic demand.
Researchers developed a technique to capture extracellular vesicles using sustainable wood cellulose-based nanofiber sheets, revealing new insights into cancer treatment. The technology has the potential to revolutionize early cancer diagnosis and open up personalized medicine.
Researchers at the University of Illinois have developed a new antifungal molecule that targets fungal cells without harming human kidney cells or other tissues. The molecule, dubbed AM-2-19, has shown significant efficacy against various fungal infections in vitro and in vivo studies.
Researchers at Texas A&M University have found a correlation between flavonoid compounds and reduced endometriosis symptoms. Flavonoids like Quercetin and Kaempferol show promise in easing inflammation, with studies suggesting they may help suppress the symptoms of inflammatory diseases like endometriosis.
Researchers from Incheon National University create gelatin patches that generate molecular oxygen to accelerate wound healing. The new hydrogels demonstrate improved coagulation, blood closure, and neovascularization in both in vitro and in vivo experiments.
Researchers at St. Jude Children's Research Hospital have determined the structure of vesicular monoamine transporter 2 (VMAT2), a protein crucial for packaging and releasing neurotransmitters in neurons. The study provides critical information for drug development to treat hyperkinetic disorders like Tourette syndrome.
Researchers developed a new class of drugs targeting PRMT5 enzyme, exploiting genetic vulnerability in tumor suppressor genes. Early clinical trials show promising results for patients with specific types of cancer, including melanoma and mesothelioma.
A study by University of Texas Health Science Center at San Antonio researchers found that corticotropin-releasing factor (CRF) activates immune cells in the dura membrane under the skull, leading to pain signals. This discovery may lead to the development of a small-molecule drug therapy to inhibit CRF and MrgprB2 interaction.
A three-year USDA grant will train healthcare and social workers in five high-risk rural Missouri counties to address childhood trauma and reduce opioid overdoses. The training covers topics such as ACEs, positive childhood experiences, and trauma-informed care.